Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Faricimab lacks proof of added benefit over comparator therapies for macular edema

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion.

December 28, 2024

Immunotherapy May Hold Promise for Skin Cancers After Kidney Transplant

The use of immune checkpoint inhibitors given as part of an immunosuppressive regimen for kidney transplant recipients with advanced cutaneous cancers may be effective and

February 14, 2024

Cybersecurity Incident at Synnovis in UK – Biotech Investments

EQS-News: SYNLAB AG / Key word(s): Statement Cybersecurity Incident at Synnovis in UK 04.06.2024 / 20:46 CET/CEST The issuer is solely responsible for the content

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.